TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3525302
Drug: Preventive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive intervention including diet, cholesterol drugs, anti-hypertensive drugs, anti-smoking advice, and increased physical activity for 6 years
Study: 19023649
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose followed by daily 75 mg maintenance dose for 28 days
Study: 19023649
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose followed by daily 10 mg maintenance dose for 28 days
Study: 24953766
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 15-20 mg/kg + 300 mg allopurinol twice a day
Study: 24953766
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 15-20 mg/kg + placebo
Study: 23161092
Drug: Personalised feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised feedback in combination with peer support
Study: 20600551
Drug: Chitosan treatment
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan treatment at concentrations of 2.5mg/mL and 5.0mg/mL for 60s to 90s
Study: 20600551
Drug: Chitosan treatment
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan treatment
Study: 16282843
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone supplementation
Study: 12121395
Drug: Desonide 0.05%
Normalized name: DESONIDE 0.05% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desonide 0.05% lotion
Study: 318952
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg/day)
Study: 318952
Drug: Spironolactone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (400 mg/day)
Study: 31395295
Drug: L-IVCD
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-IVCD
Study: 31395295
Drug: LVCD (LBBB
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVCD (LBBB or L-IVCD)
Study: 21470283
Drug: rhGH (0.067
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.067 mg/kg per day) as daily subcutaneous injections
Study: 17658525
Drug: 17alpha-hydroxyprogesterone caproate
Normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17alpha-hydroxyprogesterone caproate (17-HPC) 250 mg, i.m., 1 day before ET
Study: 11155154
Drug: Low-dose IFNalpha-2b
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFNalpha-2b (3 MU) three times weekly for 3 months (Group 2)
Study: 11155154
Drug: High-dose IFNalpha-2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFNalpha-2b (6-10 MU) three times weekly for 3 months (Group 3)
Study: 11155154
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific treatment (Control Group 1)
Study: 63749
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 750 mg desferrioxamine before transfusion
Study: 63749
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 750 mg desferrioxamine after transfusion
Study: 63749
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of 750 mg desferrioxamine over 24 hours
Study: 63749
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of desferrioxamine after transfusion
Study: 63749
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of 1500 mg desferrioxamine over 24 hours
Study: 28731567
Drug: Increased global
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased global efficiency before starting clinical treatment
Study: 26648691
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + HMG
Study: 26648691
Drug: Letrozole +
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole + HMG and CC + HMG
Study: 26648691
Drug: Letrozole +
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole + HMG, CC + HMG, HMG only
Study: 14992088
Drug: 2,000 mg
Normalized name: garlic 2,000 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 mg ascorbic acid intravenously before applying local anesthetics
Study: 14992088
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml ascorbic acid in vitro with o-toluidine
Study: 14992088
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml ascorbic acid in vitro with o-toluidine
Study: 1496538
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (daily 6 g, 30% C20:5 omega‐3 and 20% C22:6 omega‐3 as their methyl esters)
Study: 1496538
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil (daily 6g [63% C8:0 and 36% C10:0])
Study: 1496538
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (daily 6 g)
Study: 1496538
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil (daily 6g)
Study: 6363949
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methylprednisolone (MP) daily for 4 days
Study: 6363949
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg methylprednisolone (MP) daily for 4 days
Study: 6363949
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methylprednisolone (MP)
Study: 6363949
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg methylprednisolone (MP)
Study: 26545539
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake (3 mg/kg‐1)
Study: 16750468
Drug: Cilomilast 15
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast 15 mg BID (study 1)
Study: 16750468
Drug: Cilomilast 15
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast 15 mg BID (study 2)
Study: 14755134
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg) alone
Study: 14755134
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reboxetine (4 mg) and mirtazapine (15 mg)
Study: 11030508
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injections to the elbow and wrist flexors
Study: 9085752
Drug: IVUS-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVUS-guided therapy
Study: 31333252
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of drug literature abstracts
Study: 27572887
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) - Tinzaparin sodium 4500 IU subcutaneous daily injection with 500 µg folic acid once daily orally, started once positive pregnancy test till the 20th week of gestation.
Study: 27572887
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid alone (same dosage as in intervention group).
Study: 22813429
Drug: Ketamine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (specific dosage and duration not mentioned)
Study: 21166928
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose atorvastatin (40 mg daily)
Study: 18359417
Drug: Appropriate empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate empirical antibiotic therapy
Study: 14499416
Drug: rectal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: rectal placebo (RP)
Study: 14499416
Drug: rectal lidocaine
Normalized name: LIDOCAINE 50 mg in 1 g TOPICAL CREAM [Walgreens Anorectal Lidocaine Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: rectal lidocaine (RL)
Study: 14499416
Drug: oral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral lidocaine (OL)
Study: 14499416
Drug: rectal nocebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: rectal nocebo (RN)
Study: 9239162
Drug: Granisetron (KYT)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (KYT) administered for 5 consecutive days (Group B)
Study: 9239162
Drug: Granisetron (KYT)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (KYT) administered on day 1 (Group A)
Study: 12959314
Drug: Intramuscular picenadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular picenadol 50 mg
Study: 3546747
Drug: Discontinue drug
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue drug therapy and reduce overweight, excess salt, and alcohol (Group 1)
Study: 3546747
Drug: Discontinue drug
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue drug therapy with no nutritional program (Group 2)
Study: 3546747
Drug: Continue drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue drug therapy with no nutritional program (Group 3)
Study: 29462248
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy (PBC)
Study: 18474682
Drug: Plasma Tanshinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Tanshinol (TSL) from cardiotonic pills
Study: 18474682
Drug: Urinary Tanshinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary Tanshinol (TSL) from cardiotonic pills
Study: 18474682
Drug: Absorption rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Absorption rate and bioavailability of Tanshinol (TSL)
Study: 18474682
Drug: Renal excretion
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal excretion of Tanshinol (TSL)
Study: 17052637
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg (1 mL) added to articaine 4%, 1:100:000 epinephrine, 1.5 cartridges (2.7 mL)
Study: 17052637
Drug: Articaine 4%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 4%, 1:100:000 epinephrine, 1.5 cartridges (2.7 mL) and saline (1 mL)
Study: 14603582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omeprazole plus diclofenac
Study: 14603582
Drug: Selective COX‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective COX‐2 inhibitor with a PPI or misoprostol
Study: 7710561
Drug: Hyperglycaemia (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (14 mmol/l)
Study: 7710561
Drug: Euglycaemia (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (5 mmol/l)
Study: 7710561
Drug: Hypoglycaemia (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (2.5 mmol/l)
Study: 1709903
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (800 IU per kg b.w.) administered by inhalation one day prior to surgery
Study: 1709903
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (800 IU per kg b.w.) + long acting anabolic steroid (50 mg nandrolone phenylpropionate) intramuscularly
Study: 1709903
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU heparin subcutaneously on hr prior to surgery and every 12 h for the next 5 postoperative days
Study: 1709903
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (800 IU per kg b.w.)
Study: 1709903
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (800 IU per kg b.w.) + long acting anabolic steroid (50 mg nandrolone phenylpropionate)
Study: 26695922
Drug: Ambroxol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (30 mg three times per day) and Essenciale (600 mg twice daily) for 6 months
Study: 23756392
Drug: Tianeptine 12.5
Normalized name: tianeptine 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine 12.5 mg three times daily for 8 weeks
Study: 21252141
Drug: efavirenz-based ART
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz-based ART (600 mg)
Study: 21252141
Drug: nevirapine-based ART
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine-based ART (400 mg)
Study: 16920865
Drug: Iron+folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron+folic acid (FeFA) (12.5 mg Fe + 50 mug folic acid)
Study: 16920865
Drug: Iron+folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron+folic acid (FeFA) with or without Zinc (Zn) (10 mg)
Study: 12712025
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg, maximum dose 10 mg)
Study: 9255435
Drug: RheothRx Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RheothRx Injection (0.5 mg/ml)
Study: 9255435
Drug: RheothRx Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RheothRx Injection (1 mg/ml)
Study: 9255435
Drug: RheothRx Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RheothRx Injection (2 mg/ml)
Study: 9255435
Drug: RheothRx Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RheothRx Injection (5 mg/ml)
Study: 9255435
Drug: RheothRx Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RheothRx Injection (during CORE Trial)
Study: 8345429
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus platelet concentrates (10 ml/kg)
Study: 2942168
Drug: Orally-administered nickel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally-administered nickel (5.6 mg)
Study: 2942168
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of nickel
Study: 22782791
Drug: Duet (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duet (daily use)
Study: 20593911
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Study: 20593911
Drug: Up-titration from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-titration from olmesartan medoxomil 40 mg to olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Study: 20593911
Drug: Up-titration from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-titration from olmesartan medoxomil 40 mg/HCTZ 12.5 mg to olmesartan medoxomil 40 mg/HCTZ 25 mg
Study: 20593911
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of HCTZ 12.5 mg to olmesartan medoxomil 40 mg
Study: 20593911
Drug: Continuation on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation on olmesartan medoxomil 40 mg
Study: 30672832
Drug: ivabradine (Iva,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (Iva, 7.5 mg b.i.d.)
Study: 20167185
Drug: Telehealth Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth Behavioral Therapy (TBT) sessions conducted thrice weekly for 12 weeks by phone, lasting an average of 15 minutes each.
Study: 20167185
Drug: Telehealth Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth Behavioral Therapy (TBT) sessions.
Study: 18055037
Drug: Combination fibrinolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination fibrinolysis with 50 mg alteplase and tirofiban
Study: 18055037
Drug: Combination fibrinolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination fibrinolysis
Study: 8597321
Drug: Fluconazole, 200
Normalized name: Fluconazole, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, 200 mg/d for 2 weeks; then fluconazole, 200 mg/d and rifabutin, 300 mg/d for 2 weeks; then rifabutin, 300 mg/d for 2 weeks
Study: 27712932
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and clonidine (15 μg/ml)
Study: 27712932
Drug: Lidocaine and
Normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and adrenaline (12.5 μg/ml)
Study: 20305868
Drug: Combination technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination technique using Ketac and Cavit
Study: 17608134
Drug: Hydroxy methyl
Normalized name: 2-chloro-N-hydroxy methylacetamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxy methyl propyl cellulose based formulation
Study: 17608134
Drug: Poloxamer based
Normalized name: Poloxamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer based formulation
Study: 9790154
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment (CT) with clonazepam for another 5 months
Study: 9790154
Drug: Discontinuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation treatment (DT) using a clonazepam taper at the rate of 0.25 mg every 2 weeks
Study: 9790154
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment (CT)
Study: 9790154
Drug: Discontinuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation treatment (DT)
Study: 7815837
Drug: Salvage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatment after initial induction
Study: 7815837
Drug: Consolidation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation treatment (standard maintenance, intensive consolidation courses, autologous or allogeneic transplantation)
Study: 28351410
Drug: Cognitive‐Behavioral Rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Rehabilitation (12 weekly group sessions of 90 min each)
Study: 26708885
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy (dendritic cells and cytokine‐induced killer cells, DC‐CIK) combined with chemotherapy
Study: 26708885
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy (DC‐CIK) combined with chemotherapy
Study: 21209881
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment
Study: 16789988
Drug: Cefepime 2G
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime 2G 12 hourly
Study: 16789988
Drug: Ampicillin/Sulbactam 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/Sulbactam 3 g 8 hourly and Aztreonam 2 g 8 hourly
Study: 12832310
Drug: Intensive Therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Therapy (IT)
Study: 8842575
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate + Acetazolamide infusion
Study: 1616890
Drug: 5-fluorouracil (5FU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5FU), 13.5 mg/kg for five days (arm A)
Study: 1616890
Drug: High-dose folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folinic acid (FA), 200 mg/m2 for five days and 5FU, 400 mg/m2 for five days (arm B)
Study: 6387968
Drug: Hexoprenaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline (10 micrograms administered intravenously 5 minutes before amniocentesis)
Study: 30682037
Drug: Dengue vaccine
Normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue vaccine with a true VE of 0.8
Study: 29533864
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin administration within the first minute following the delivery of the fetus (10 IU)
Study: 29533864
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin administration immediately following placental delivery (10 IU)
Study: 26751193
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus hesperidin (500 g hesperidin with 500 mg calcium)
Study: 15831773
Drug: Fenofibrate (201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (201 mg/d)
Study: 17394563
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg twice daily)
Study: 15831773
Drug: Combined fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined fenofibrate (201 mg/d) plus rosiglitazone (4 mg twice daily)
Study: 8998248
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) 5 to 10 mg once daily
Study: 8998248
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 to 25 mg once daily